We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Provectus Pharmaceuticals Inc.
An SI Board Since April 2006
Posts SubjectMarks Bans Symbol
13111 103 0 PVCT
Emcee:  Jack Russell Type:  Moderated

This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.

Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline

Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at


PV-10 link to video and visual references:

PV-10 Trial Participants Telling Their Own Stories in the News

May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.
Video can be viewed here.

This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.
Video can be viewed here.

2008, Charles Dawson, PV10 patient, Australia; Professor John Thompson, Sydney Melanoma Unit

Video can be viewed here

December 16, 2010
Madja Rauh recently traveled to Bethlehem with her daughter Ursa Rauh from Ljubljana, the capital of Slovenia in Europe, to receive a promising, experimental treatment for metastatic melanoma with internationally recognized melanoma investigator Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology, St. Luke's Hospital & Health Network,Bethlehem, PA

Video can be viewed here.
Madja Rauh, PV10 patient, has a Facebook page as of 1/ 2015
Madja Rauh, PV-10 patient, has a Facebook page as of January 2015


Contact Info

Our Contact Form
Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
Laura Skorny
1717 Arch Street, Suite 1300
Philadelphia, PA 19103
Telephone: +1 (610) 649-7300
Fax: +1 (610) 649-7302

Investor Relations:
Porter, LeVay & Rose, Inc.
Marlon A. Nurse
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
Fax: 212-244-3075

Media Relations:
Porter, LeVay & Rose, Inc.
Bill Gordon
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700

Investment Advisor:
Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
13111What's happening? Price up. volume up. I thought my computer was acting up!Bob Miller-12/1/2022
13110April 1 gets me thinking about PVCT again, any real progress in the past year?NTTG-4/1/2019
13109What a run-away success story. How is that PIII trial coming along, any day now?NTTG-5/21/2018
13108Double since then...Jack Russell-4/20/2018
13107Almost 4 cents a share....seems more like an agonal gaspNTTG-10/25/2017
13106Its alive! LOLJack Russell-10/17/2017
13105Too little Too late, BOD should have taken their role seriously years ago. FunnyNTTG-12/28/2016
13104Ditto Jack.Howard Williams111/17/2016
13103I am pretty much done... I will hold my shares if something happens great if notJack Russell-11/16/2016
13102I have not traded or followed PVCT on a regular basis since MGT finally admittedNTTG-11/14/2016
13101But I still wonder... As right as you have been ( which you have) why do you eveJack Russell-11/4/2016
13100At this point you get no argument from me...Jack Russell-11/4/2016
13099MGT track record of successNTTG-10/17/2016
13098Starting to look more realistic that PVCT will de-list...even a r/s with creativNTTG-10/7/2016
13097SG...would not be surprised to learn that Pete and Eric have both signed up for NTTG-10/3/2016
13096Right, the high speed free fall in SP has slowed a bit, but PVCT will run short NTTG-9/19/2016
13095Bullish cross in MACD and Stochastic oscillator. [graphic]hollyhunter-9/19/2016
13094Hey NTTG, Thanks very much for your reply. My cynicism is untouched but some prSG-9/14/2016
13093Hey SG, hope all is going well. I got a similar string of mailings recently, thNTTG19/14/2016
13092Wow, there are still longs here. I just got a too late note about my membership SG-9/12/2016
13091We actually agree...Jack Russell-8/26/2016
13090Offerings are getting stranger and stranger. BOD should have gotten rid of Pete NTTG-8/25/2016
13089Still no warrant exchange takers...where do Pete and the Posse go now for $$ to NTTG-7/29/2016
13088No takers for the June 28 warrant exchange Gotta gNTTG-6/29/2016
13087I doubt it... But you never know. What makes you think this?Jack Russell-6/21/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):